Interpretation and comparison of international guidelines for salivary gland malignancy in 2021.
10.3760/cma.j.cn112144-20210715-00331
- VernacularTitle:2021年唾液腺恶性肿瘤两种国际指南的解读与比较
- Author:
Ya Hui WANG
1
;
Zhi Yong LI
2
;
Qian Ming CHEN
1
Author Information
1. Stomatology Hospital, School of Stomatology, Zhejiang University School of Medince & Clinical Research Center for Oral Diseases of Zhejiang Province & Key Laboratory of Oral Biomedical Research of Zhejiang Province & Cancer Center of Zhejiang University, Hangzhou 310006, China.
2. Department of Oral Oral and Maxillofacial Surgery, Stomatology Hospital, School of Stomatology, Zhejiang University School of Medince & Clinical Research Center for Oral Diseases of Zhejiang Province & Key Laboratory of Oral Biomedical Research of Zhejiang Province & Cancer Center of Zhejiang University, Hangzhou 310006, China.
- Publication Type:Journal Article
- MeSH:
China;
Humans;
Salivary Gland Neoplasms/therapy*
- From:
Chinese Journal of Stomatology
2022;57(2):136-141
- CountryChina
- Language:Chinese
-
Abstract:
In order to provide evidence-based recommendations on the management of salivary gland malignancy (SGM), the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) formulated and updated SGM clinical practice guidelines respectively in 2021.The two guidelines are interpreted and compared in this article from six perspectives including preoperative evaluations, surgical diagnostic and therapeutic procedures, appropriate radiotherapy techniques, the role of systemic therapy, follow-up evaluations and recurrent-metastatic diseases' management of SGM, which has guiding significance for diagnosis and treatment of SGM in China.
